Navigation Links
AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
Date:9/25/2008

QUEBEC CITY, Sept. 25 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its President and CEO, Jrgen Engel, PhD, will present a company overview at BioContact Quebec on Thursday, October 2, 2008, at 2:00 pm (eastern time) in the Salle Frontenac of the Fairmont Le Chateau Frontenac hotel in Quebec City, Canada.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at http://www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
4. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
5. AEterna Zentaris Sells Quebec City Building for $7.1 million
6. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
7. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
8. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
9. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
10. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
11. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that Biohaven has issued today the following press ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding ... the U.S. Food and Drug Administration ("FDA") has granted ... candidate BHV-0223, an orally dissolving tablet being developed for ...
(Date:12/8/2016)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ... today announced financial results for the fiscal first ... on our commitment to address an unmet medical ... pleased with the early clinical response data presented ... focused on advancing our lead program – ImmunoPulse® ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment ... and President of Eurofins Scientific Inc. (ESI). Mr. ... his proven professional and entrepreneurial experience in leading international business teams. ... US food testing market to uphold Eurofins, status as the global ... ...
(Date:12/8/2016)... BARCELONA, Spain , Dec. 8, 2016  Anaconda ... on the development of the next generation neuro-thrombectomy system ... the appointment of Tudor G. Jovin, MD to join ... to serve as a strategic network of scientific and ... progresses the development of the ANCD BRAIN ® ...
Breaking Biology Technology:
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):